CA2380339A1 - Method of diagnosis of cardiac hypertrophy - Google Patents

Method of diagnosis of cardiac hypertrophy Download PDF

Info

Publication number
CA2380339A1
CA2380339A1 CA002380339A CA2380339A CA2380339A1 CA 2380339 A1 CA2380339 A1 CA 2380339A1 CA 002380339 A CA002380339 A CA 002380339A CA 2380339 A CA2380339 A CA 2380339A CA 2380339 A1 CA2380339 A1 CA 2380339A1
Authority
CA
Canada
Prior art keywords
cardiac hypertrophy
levels
sample
bodily fluid
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380339A
Other languages
English (en)
French (fr)
Inventor
Anthony Michael Heagerty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MATRIX THERAPEUTICS Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9915881.8A external-priority patent/GB9915881D0/en
Application filed by Individual filed Critical Individual
Publication of CA2380339A1 publication Critical patent/CA2380339A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002380339A 1999-07-08 2000-06-29 Method of diagnosis of cardiac hypertrophy Abandoned CA2380339A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14277599P 1999-07-08 1999-07-08
GBGB9915881.8A GB9915881D0 (en) 1999-07-08 1999-07-08 Methods of diagnosis
GB9915881.8 1999-07-08
US60/142,775 1999-07-08
PCT/GB2000/002521 WO2001003573A2 (en) 1999-07-08 2000-06-29 Method of diagnosis of cardiac hypertrophy

Publications (1)

Publication Number Publication Date
CA2380339A1 true CA2380339A1 (en) 2001-01-18

Family

ID=26315738

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380339A Abandoned CA2380339A1 (en) 1999-07-08 2000-06-29 Method of diagnosis of cardiac hypertrophy

Country Status (6)

Country Link
EP (1) EP1196781A2 (de)
JP (1) JP2003504602A (de)
CN (1) CN1370277A (de)
AU (1) AU5693300A (de)
CA (1) CA2380339A1 (de)
WO (1) WO2001003573A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117410A1 (es) * 2005-04-28 2006-11-09 Proyecto De Biomedicina Cima, S.L. Uso de un fragmento c-terminal de cardiotrofina-1 como marcador de cardiotrofina-1
DE102006034142A1 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
CN108254576B (zh) * 2018-01-25 2020-08-04 南京医科大学 一种腺嘌呤核苷酸转运体1的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor

Also Published As

Publication number Publication date
WO2001003573A2 (en) 2001-01-18
EP1196781A2 (de) 2002-04-17
CN1370277A (zh) 2002-09-18
AU5693300A (en) 2001-01-30
WO2001003573A3 (en) 2001-10-11
JP2003504602A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
Litwin et al. Inflammatory activation in children with primary hypertension
JP2022171936A (ja) 心臓血管疾患及び事象のための診断及び予後方法
JP4523587B2 (ja) Ａ型及びｂ型急性大動脈解離と急性心筋梗塞の鑑別方法及び鑑別用キット
JP2002538463A (ja) 脳卒中を診断しそして区別するための方法
JP6562915B2 (ja) 心血管疾患または心血管イベントを有するリスクを予測するための方法およびキット
JP2006038877A (ja) 腎臓病の検出方法
KR20100128281A (ko) 바이오마커 와이케이엘-40의 수준을 측정함으로써 발견되는 생존 예후에 따른 심혈관계 질환에 걸린 개체들의 분류 방법
JP6283319B2 (ja) 抗ＨＢｃ定量的検出方法、並びに慢性Ｂ型肝炎患者の疾患進行の監視及び管理並びに治療効果の予測におけるその使用
CA2264939A1 (en) Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
US7445886B2 (en) Macrophage migration inhibitory factor as a marker for cardiovascular risk
US7709215B2 (en) Method for diagnosing and treating acute joint injury
Carrozza et al. Levothyroxine replacement therapy in central hypothyroidism: a practice report
CN116547536A (zh) 用于预测患有covid-19的患者的疾病严重度的gdf-15
Li et al. Relationship between endothelial dysfunction and prevalence of chronic kidney disease: the circulatory risk in communities study (CIRCS)
CA2380339A1 (en) Method of diagnosis of cardiac hypertrophy
CN116097099A (zh) 用于评定无症状脑梗死和认知衰退的esm-1
Ansar et al. C-reactive protein: A clinical marker in cardiovascular disease
JP2020533586A (ja) 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
JP2022022635A (ja) 自己免疫性肝炎を判定するためのバイオマーカー
CA3182149A1 (en) Compositions comprising gelsolin for treating frailty
Squire et al. Improved sensitivity and precision of thyroid-stimulating hormone measurements by standardizing signal reagent addition in the Amerlite TSH 30 assay
Elnahar et al. False elevation of cardiac markers: importance of recognition
Stubbs Cardiac troponin t and myocardial damage
US20150104463A1 (en) Methods and kits for predicting the risk of having a cardiovascular event in a subject
EP2697651A1 (de) Biomarker für schmerzintensität

Legal Events

Date Code Title Description
FZDE Discontinued